Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Solid drug for oral use

一种药物、剂型的技术，应用在口服形式的固体药物领域，能够解决没有教导或提示等问题

Inactive Publication Date: 2006-01-25
KISSEI PHARMA
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, Patent Document 2 has no teaching or prompting effect on the present invention at all

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solid drug for oral use
  • Solid drug for oral use
  • Solid drug for oral use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Capsules containing 2.0 mg KMD-3213

[0130] Thoroughly mix 2.0 parts of KMD-3213, 134.4 parts of D-mannitol, 26.0 parts of partially pregelatinized starch (PCS (registered trademark), Asahi Chemical Industry Co., Ltd) and 9.0 parts of partially pregelatinized starch (Starch 1500 (registered trademark) trademark), Japan Colorcon Co., Ltd). An appropriate amount of water is added, and the mixture is granulated. The particles were dried with a fluidized bed dryer at an inlet temperature of 60°C until the exhaust temperature reached 40°C, and then sieved. A mixture of 1.8 parts of magnesium stearate and 1.8 parts of sodium lauryl sulfate was added to the sieved granules, mixed for 5 minutes, and the mixture was filled into capsule shells to prepare capsules containing 2.0 mg of KMD-3213.

Embodiment 2

[0132] Capsules containing 4.0 mg KMD-3213

[0133] Thoroughly mix 4.0 parts of KMD-3213, 132.4 parts of D-mannitol, 26.0 parts of partially pregelatinized starch (PCS (registered trademark), Asahi Chemical Industry Co., Ltd) and 9.0 parts of partially pregelatinized starch (Starch 1500 (registered trademark) trademark), Japan Colorcon Co., Ltd). An appropriate amount of water is added, and the mixture is granulated. The particles were dried with a fluidized bed dryer at an inlet temperature of 60°C until the exhaust temperature reached 40°C, and then sieved. A mixture of 1.8 parts of magnesium stearate and 1.8 parts of sodium lauryl sulfate was added to the sieved granules, mixed for 5 minutes, and the mixture was filled into capsule shells to prepare capsules containing 4.0 mg of KMD-3213.

Embodiment 3

[0135] Tablets containing 4.0 mg KMD-3213

[0136] 4.0 parts of KMD-3213, 117.0 parts of D-mannitol, and 7.0 parts of low-substituted hydroxypropylcellulose (L-HPC (registered trademark), Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed. A 12% aqueous solution of hydroxypropylcellulose (4 parts of hydroxypropylcellulose and about 30 parts of water) was added and the mixture was granulated. Dry the particles with a fluidized bed dryer at an inlet temperature of 60°C until the exhaust temperature reaches 40°C, dry and sieve and pass through a sieve. Add 1.0 parts magnesium stearate to the granules and mix for 3 minutes. The mixture was compressed into tablets and coated with a coating agent to prepare tablets containing 4.0 mg of KMD-3213.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a solid oral dosage form pharmaceutical for the treatment of dysuria, which comprises, as an active ingredient, an indoline compound having an alpha 1 -adrenoceptor blocking activity and represented by the formula: a prodrug thereof, pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, wherein said pharmaceutical is prepared to have 85% dissolution time of not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water.

Description

technical field [0001] The present invention relates to solid medicaments in oral form for the treatment of dysuria. More specifically, the present invention relates to a solid oral dosage form medicine for treating dysuria, which comprises an indoline compound having α 1 - Adrenergic receptors (hereinafter referred to as "α 1 -AR") blocking activity, can be represented by chemical formula (I) (hereinafter referred to as "KMD-3213"): [0002] [0003] Also relate to its drug prodrug, pharmaceutically acceptable salt or pharmaceutically acceptable solvate, according to Japanese Pharmacopoeia method 2 (paddle method), under the condition that water is used as test medium and paddle speed is 50rpm, they are in dissolution test The time to dissolve 80% in the medium should not exceed 60 minutes. [0004] The present invention also relates to a solid oral dosage form medicine for treating dysuria, said medicine comprising 1) KMD-3213, its prodrug, pharmaceutically acceptable ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4045A61K45/00A61K47/10A61K47/12A61K9/20A61K9/28A61K9/48A61P13/00A61P13/02A61P43/00A61K9/16
CPCA61K31/4045A61K9/1652A61K9/1623A61K9/2018A61K9/2054A61K9/4866A61P13/00A61P13/02A61P13/04A61P13/08A61P13/10A61P25/02A61P29/00A61P31/04A61P43/00A61P7/12A61K9/20A61K9/28A61K9/48
Inventor 永沼剛村松三夫
Owner KISSEI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com